Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxcyte, Inc. - Common Stock (NQ:PCVX)

30.43 -3.25 (-9.66%)
Streaming Delayed Price Updated: 11:55 AM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vaxcyte, Inc. - Common Stock

< Previous 1 2 3 Next >
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Top stock movements in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Monday's session: top gainers and losers
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
What's Driving the Market Sentiment Around Vaxcyte?
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga
(PCVX) - Analyzing Vaxcyte's Short Interest
Via Benzinga
(PCVX) - Analyzing Vaxcyte's Short Interest
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
These stocks are gapping in today's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Monday's pre-market session: top gainers and losers
Wondering what's happening in Monday's pre-market session? Find an overview in this article. 
Via Chartmill
Peering Into Vaxcyte's Recent Short Interest
Via Benzinga
Peering Into Vaxcyte's Recent Short Interest
Via Benzinga
Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
Via Benzinga
Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies. 
Via Investor's Business Daily
Exposures Product Safety
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine
Vaxcyte's VAX-24 Phase 2 trial showed a safety profile similar to PCV20, with strong immune responses and no serious vaccine-related adverse events. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
One Vanguard Index Fund to Buy That May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Via The Motley Fool
Topics Stocks
Exposures US Equities
Are Small-Cap Stocks A Buy After Russell 2000 Correction?
Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines. 
Via Benzinga
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
Via The Motley Fool
Topics Stocks
Exposures US Equities
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
Via The Motley Fool
Topics Stocks
Exposures US Equities
Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
10 worst performing large-cap stocks last week: MPWR, SMCI, MRNA, LDOS, MNDY, PCVX, BAH, ABBV, CACI, XPEV. Check if they're in your portfolio. 
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... 
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. 
Via Investor's Business Daily
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.